Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2019

Open Access 01-01-2019 | Clinical Guides in Oncology

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

Authors: E. González-Flores, R. Serrano, I. Sevilla, A. Viúdez, J. Barriuso, M. Benavent, J. Capdevila, P. Jimenez-Fonseca, C. López, R. Garcia-Carbonero

Published in: Clinical and Translational Oncology | Issue 1/2019

Login to get access

Abstract

NENs are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise across all sites, stages and grades. Although improved diagnostic techniques have led to earlier detection and stage migration, the improved prognosis documented over time for advanced gastrointestinal and pancreatic neuroendocrine tumors also reflect improvements in therapy. The aim of this guideline is to update practical recommendations for the diagnosis and treatment of gastroenteropancreatic and lung NENs. Diagnostic procedures, histological classification and therapeutic options are briefly discussed, including surgery, liver-directed therapy, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, and treatment algorithms are provided.
Literature
1.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRefPubMedPubMedCentral
2.
Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual A, Benavent M, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the WHO 2010. Oncologist. 2018;22:1–11.
3.
García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, et al. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014;16(3):243–56.CrossRefPubMed
4.
Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs. Ann Nucl Med. 2015;29(1):1–7.CrossRefPubMed
5.
Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186–92.CrossRefPubMed
6.
Klöppel G, Klimstra DS, Hruban RH, Adsay V, Capella C, Couvelard A, et al. Pancreatic Neuroendocrine tumors: update on the New World Health Organization Classification. AJSP Rev Rep. 2017;22(5):233–9.
7.
8.
9.
Capdevila J, Castellano D, Díaz Pérez JA, Escudero P, Navarro L, Segura Á, Grande E, Salazar R, Sevilla I, López G. Guía práctica de diagnóstico, tratamiento y seguimiento de Tumores Neuroendocrinos. 3a Edición. Barcelona: Edika Med SL; 2016.
10.
Yuan CH, Wang J, Xiu DR, Tao M, Ma ZL, Jiang B, et al. Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases. Ann Surg Oncol. 2016;23(1):244–9.CrossRefPubMed
11.
Vilchez V, Gedaly R. Liver transplantation for the treatment of neuroendocrine liver metastases. Best Pract Res Clin Endocrinol Metab. 2016;30(1):141–7.CrossRefPubMed
12.
Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long term follow-up. Surgery. 2010;148(6):1288–93.CrossRefPubMed
13.
Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases-a systematic review. Surg Oncol. 2012;21(4):299–308.CrossRefPubMed
14.
Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver Metastases Consensus Conference. HP (Oxf). 2015;17(1):29–37.CrossRef
15.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.CrossRefPubMed
16.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.CrossRefPubMed
17.
Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol. 2017;35(15):1695–703.CrossRefPubMedPubMedCentral
18.
Clewemar Antonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Erikson B. Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology. 2016;103:345–53.CrossRefPubMed
19.
Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36 (suppl; abstr 4004).
20.
Fazio N, Ungaro A, Spada F, Cella CA, Pisa E, Barberis M, et al. The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. J Thorac Dis. 2017;9(suppl 15):S1501–10.CrossRefPubMedPubMedCentral
21.
Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–43.PubMed
22.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.CrossRefPubMedPubMedCentral
23.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.CrossRefPubMed
24.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMedPubMedCentral
25.
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue (90Y-DOTA)-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23.CrossRefPubMed
26.
Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22:657–64.CrossRefPubMed
27.
Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, et al. Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas. J Natl Cancer Inst. 2017;109(5):djw277. https://​doi.​org/​10.​1093/​jnci/​djw277.CrossRef
28.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152–60.CrossRefPubMed
29.
Chan DL, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, et al. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): a practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology. 2018;107(1):32–41.CrossRefPubMed
Metadata
Title
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
Authors
E. González-Flores
R. Serrano
I. Sevilla
A. Viúdez
J. Barriuso
M. Benavent
J. Capdevila
P. Jimenez-Fonseca
C. López
R. Garcia-Carbonero
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1980-7

Other articles of this Issue 1/2019

Clinical and Translational Oncology 1/2019 Go to the issue

Clinical Guides in Oncology

SEOM clinical guidelines on nutrition in cancer patients (2018)

Clinical Guides in Oncology

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)

Clinical Guides in Oncology

SEOM clinical guidelines to primary prevention of cancer (2018)

Acknowledgement to Reviewers

Thanks to reviewers 2018

Clinical Guides in Oncology

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

Editorial

SEOM guidelines 2018
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits